Vitrolife Management

Management criteria checks 2/4

Vitrolife's CEO is Bronwyn Brophy O´Connor, appointed in Aug 2023, has a tenure of 1.25 years. total yearly compensation is SEK7.44M, comprised of 74.5% salary and 25.5% bonuses, including company stock and options. directly owns 0.014% of the company’s shares, worth SEK4.28M. The average tenure of the management team and the board of directors is 1.3 years and 6.8 years respectively.

Key information

Bronwyn Brophy O´Connor

Chief executive officer

SEK 7.4m

Total compensation

CEO salary percentage	74.5%
CEO tenure	1.3yrs
CEO ownership	0.01%
Management average tenure	1.3yrs
Board average tenure	6.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Bronwyn Brophy O´Connor's remuneration changed compared to Vitrolife's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	-SEK 4b
Jun 30 2024	n/a	n/a	-SEK 4b
Mar 31 2024	n/a	n/a	-SEK 4b
Dec 31 2023	SEK 7m	SEK 6m	-SEK 4b

Compensation vs Market: Bronwyn's total compensation ($USD673.62K) is below average for companies of similar size in the UK market ($USD2.68M).

Compensation vs Earnings: Insufficient data to compare Bronwyn's compensation with company performance.

CEO

Bronwyn Brophy O´Connor (50 yo)

1.3yrs

Tenure

SEK 7,439,000

Compensation

Ms. Bronwyn Brophy O´Connor is President and Chief Executive Officer at Vitrolife AB (publ) since joining from August 01, 2023. She has an impressive track record as a leader of global Life science and Med...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Bronwyn Brophy O´Connor	CEO & President	1.3yrs	SEK 7.44m	0.014% SEK 4.3m
Patrik Tolf	Chief Financial Officer	2.8yrs	no data	0.0096% SEK 2.9m
Claus Bisgaard	Senior Vice President of Technologies	no data	no data	0.00028% SEK 83.9k
Guillermo Ferrando	Vice President Strategy & Corporate development	1.8yrs	no data	no data
Olivia Natens	Senior Vice President of Sales & Marketing	less than a year	no data	no data
Frank Pettersson	Acting Senior Vice President of HR & Sustainability	1.1yrs	no data	0.0013% SEK 392.7k
Rickard Ericsson	Senior Vice President of Consumables	less than a year	no data	0.0061% SEK 1.8m
Ricardo Capella	Senior Vice President Genetic Services	2.8yrs	no data	0.0044% SEK 1.3m

1.3yrs

Average Tenure

53.5yo

Average Age

Experienced Management: 0YAY's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Henrik Blomquist	Director	5.5yrs	SEK 883.00k	0.0081% SEK 2.4m
Jon Sigurdsson	Chairman of the Board	9.8yrs	SEK 16.30m	0.022% SEK 6.7m
Lars Holmqvist	Independent Director	6.8yrs	SEK 450.00k	no data
Pia Marions	Independent Director	11.6yrs	SEK 500.00k	0.0037% SEK 1.1m
Karen Soerensen	Independent Director	4.4yrs	SEK 500.00k	no data

6.8yrs

Average Tenure

62yo

Average Age

Experienced Board: 0YAY's board of directors are considered experienced (6.8 years average tenure).

Vitrolife Management

Management criteria checks 2/4

Key information

Recent management updates

Vitrolife AB (Publ) Announces Election Committee Appointments

Director recently bought kr1.6m worth of stock

Vitrolife AB (publ) Announces Election Committee Appointments

Vitrolife AB (publ) Announces Resignation of Maria Forss as Senior Vice President

Insufficient new directors

Vitrolife AB Announces Board Changes

Recent updates

Vitrolife AB (publ) to Report Fiscal Year 2024 Final Results on Mar 27, 2025

Vitrolife AB (publ) to Report Q4, 2025 Results on Jan 29, 2026

Third quarter 2024 earnings released: EPS: kr0.86 (vs kr0.90 in 3Q 2023)

Vitrolife AB (Publ) Announces Election Committee Appointments

Now 23% overvalued after recent price rise

Now 21% overvalued after recent price rise

Vitrolife AB (publ) to Report Q3, 2025 Results on Oct 29, 2025

Second quarter 2024 earnings released: EPS: kr1.06 (vs kr0.78 in 2Q 2023)

Vitrolife AB (publ) (OM:VITR) acquired Stb Zorg B.V.

Director recently bought kr1.6m worth of stock

Vitrolife AB (publ) (OM:VITR) signed an agreement to acquire Stb Zorg B.V. for €18 million.

Vitrolife AB (Publ) Approves Dividend for the Financial Year 2023

Upcoming dividend of kr1.00 per share

Now 20% undervalued

First quarter 2024 earnings released: EPS: kr0.85 (vs kr0.74 in 1Q 2023)

Dividend increased to kr1.00

Full year 2023 earnings released: kr28.44 loss per share (vs kr2.91 profit in FY 2022)

Vitrolife AB (publ) to Report Fiscal Year 2023 Final Results on Mar 27, 2024

Vitrolife AB (Publ) Reports Non-Cash Impairment for the Fourth Quarter of 2023

Investor sentiment improves as stock rises 15%

Third quarter 2023 earnings released: EPS: kr0.90 (vs kr0.80 in 3Q 2022)

Vitrolife AB (publ) Announces Election Committee Appointments

Vitrolife AB (publ) Announces Resignation of Maria Forss as Senior Vice President

Insufficient new directors

Vitrolife AB Announces Board Changes

Chief Financial Officer recently bought kr335k worth of stock

Investor sentiment deteriorates as stock falls 21%

New minor risk - Share price stability

Second quarter 2023 earnings released: EPS: kr0.78 (vs kr0.96 in 2Q 2022)

Vitrolife AB (publ) to Report Q3, 2024 Results on Oct 24, 2024

Chief Financial Officer recently bought kr535k worth of stock

Upcoming dividend of kr0.85 per share at 0.4% yield

Full year 2022 earnings released: EPS: kr2.91 (vs kr2.98 in FY 2021)

Full year 2022 earnings released: EPS: kr2.91 (vs kr2.98 in FY 2021)

Vitrolife AB (publ) Proposes Dividend for 2022

Vitrolife AB (publ) Announces Executive Changes

Second quarter 2022 earnings released: EPS: kr0.96 (vs kr0.79 in 2Q 2021)

Investor sentiment improved over the past week

Vitrolife AB (publ) to Report First Half, 2023 Results on Jul 14, 2023

Vitrolife AB (publ) Announces Election Committee Appointments

Now 29% undervalued after recent price drop

Investor sentiment deteriorated over the past week

Vitrolife AB (Publ) Announces Retirement of Thomas Axelsson as CEO

Second quarter 2022 earnings released: EPS: kr0.96 (vs kr0.79 in 2Q 2021)

Vitrolife AB (publ), Annual General Meeting, Apr 27, 2023

Chief Financial Officer recently bought kr496k worth of stock

First quarter 2022 earnings released: EPS: kr0.61 (vs kr1.09 in 1Q 2021)

First quarter 2022 earnings released: EPS: kr0.61 (vs kr1.09 in 1Q 2021)

Upcoming dividend of kr0.80 per share

Vitrolife AB (Publ) Proposes Dividend

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Vitrolife AB (Publ) Proposes Dividend

Third quarter 2021 earnings released: EPS kr0.89 (vs kr0.81 in 3Q 2020)

Second quarter 2021 earnings released: EPS kr0.79 (vs kr0.11 in 2Q 2020)

Vitrolife AB (publ) Approves Dividend for the Financial Year 2020

First quarter 2021 earnings released: EPS kr1.09 (vs kr0.73 in 1Q 2020)

Upcoming dividend of kr0.80 per share

Full year 2020 earnings released: EPS kr2.64 (vs kr3.53 in FY 2019)

Full year 2020 earnings released: EPS kr2.64 (vs kr3.53 in FY 2019)

Revenue misses expectations

New 90-day high: kr237

Vitrolife AB (publ) to Report Fiscal Year 2020 Results on Feb 10, 2021

New 90-day low: kr209

Revenue beats expectations

Third quarter 2020 earnings released: EPS kr0.81

Vitrolife AB (publ) to Report Fiscal Year 2020 Results on Mar 30, 2021

Vitrolife AB (publ) to Report Q1, 2021 Results on Apr 22, 2021

Vitrolife AB (Publ) Announces Appointment of Election Committee

New 90-day high - kr246